线粒体丙酮酸载体在异柠檬酸脱氢酶突变型胶质瘤中的预后作用
该研究基于癌症基因组图谱中286例低级别胶质瘤(WHO II和III级)的基因组与临床数据,采用Kaplan-Meier分析和风险建模评估MPC1与MPC2表达对患者预后的影响,并在包含胶质母细胞的额外数据集中验证;结果显示MPC1 z-score > 0与IDH突变型肿瘤生存改善相关,MPC2 z-score > 0与生存恶化相关,基于IDH和1p19q状态、年龄、KPS评分及MPC1和MPC2 z评分的临床风险评分定义了4个风险类别并得到验证。
要点
- 在IDH突变型低级别胶质瘤中,MPC1 z-score > 0与生存改善相关(p < 0.01),MPC2 z-score > 0与生存恶化相关(p < 0.01)。
- MPC1状态在1p19q共缺失肿瘤中区分生存改善(p < 0.05),MPC2表达在1p19q完整肿瘤中区分生存恶化(p < 0.01)。
- 风险模型识别IDH和1p19q状态、年龄(p = 0.01,HR = 1.03)、KPS评分(p = 0.03,HR = 0.97)和MPC1(p = 0.003,HR = 0.52)为影响总生存的关键变量,MPC2未达显著(p = 0.38)。
核心结论
- 这些结果支持MPC尤其是MPC1在改善IDH突变型肿瘤预后判断中的重要性,风险评分系统将这一发现直接转化为临床应用,但需要进一步研究以改善对MPC在胶质瘤代谢基因组调控中作用的分子理解。
研究设计与样本
- 研究评估了来自癌症基因组图谱(TCGA)的286例低级别胶质瘤(WHO II和III级)患者的基因组和临床数据,使用Kaplan-Meier分析和风险建模,并用包含胶质母细胞瘤的额外数据集进行验证。
主要发现
- 286例低级别胶质瘤患者(平均年龄42.7 ± 13.5岁,55.6%为男性)包括54例IDH野生型(18.9%)、140例IDH突变且1p19q完整(49.0%)和85例IDH突变且1p19q共缺失(29.7%)肿瘤。
- Kaplan-Meier分析显示MPC1 z-score > 0区分出更好的生存,尤其在IDH突变型肿瘤中(p < 0.01),但在IDH野生型肿瘤中无此作用。
- MPC2 z-score > 0识别出更差的生存,尤其在IDH突变型肿瘤中(p < 0.01),但在IDH野生型肿瘤中无此作用。
- 在包含5% IDH突变型病例的胶质母细胞瘤数据集中,MPC1和MPC2均无预测作用。
- 在按IDH分层的低级别胶质瘤数据集中,MPC1状态在1p19q共缺失肿瘤中区分出生存改善(p < 0.05),而MPC2表达在1p19q完整肿瘤中 delineate 出生存恶化(p < 0.01)。
关键数值与推荐
- 风险模型识别IDH和1p19q状态、年龄(p = 0.01,HR = 1.03)、KPS评分(p = 0.03,HR = 0.97)和MPC1(p = 0.003,HR = 0.52)为影响总生存的关键变量,MPC2未达显著(p = 0.38)。
- 进一步验证确认MPC1为低级别胶质瘤的独立预测因子。
- 使用IDH和1p19q状态、年龄、KPS评分及MPC1和MPC2 z评分的临床风险评分定义了低级别胶质瘤的4个风险类别,该评分使用次要胶质瘤数据集进行了验证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以改善对MPC在胶质瘤代谢基因组调控中作用的分子理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Gliomas are one of the most common types of primary brain tumors. Recent studies have supported the importance of key genetic alterations, including isocitrate dehydrogenase (IDH) mutations and 1p19q codeletion, in glioma prognosis. Mutant IDH produces 2-hydroxyglutarate from α-ketoglutarate, a key metabolite of the Krebs cycle. The mitochondrial pyruvate carrier (MPC) is composed of MPC1 and MPC2 subunits and is functionally essential for the Krebs cycle. The authors sought to explore the impact of MPC1 and MPC2 expression on patient prognosis. METHODS Genomic and clinical data in patients with lower-grade glioma (WHO grades II and III) from The Cancer Genome Atlas (TCGA) were evaluated using Kaplan-Meier analysis and hazards modeling. Validation was conducted with additional data sets, including glioblastoma. RESULTS A total of 286 patients with lower-grade glioma (mean age 42.7 ± 13.5 years, 55.6% males) included 54 cases of IDH-wild type (18.9%); 140 cases of IDH-mutant, 1p19q-intact (49.0%); and 85 cases of IDH-mutant, 1p19q-codeleted (29.7%) tumors. Kaplan-Meier analysis showed that an MPC1 z-score > 0 distinguished better survival, particularly in IDH-mutant (p < 0.01) but not IDH-wild type tumors. Conversely, an MPC2 z-score > 0 identified worsened survival, particularly in IDH-mutant (p < 0.01) but not IDH-wild type tumors. Consistently, neither MPC1 nor MPC2 was predictive in a glioblastoma data set containing 5% IDH-mutant cases. Within the IDH-stratified lower-grade glioma data set, MPC1 status distinguished improved survival in 1p19q-codeleted tumors (p < 0.05), whereas MPC2 expression delineated worsened survival in 1p19q-intact tumors (p < 0.01). A hazards model identified IDH and 1p19q status, age (p = 0.01, HR = 1.03), Karnofsky Performance Scale (KPS) score (p = 0.03, HR = 0.97), and MPC1 (p = 0.003, HR = 0.52) but not MPC2 (p = 0.38) as key variables affecting overall survival. Further validation confirmed MPC1 as an independent predictor of lower-grade glioma. A clinical risk score using IDH and 1p19q status, age, KPS score, and MPC1 and MPC2 z-scores defined 4 risk categories for lower-grade glioma; this score was validated using a secondary glioma data set. CONCLUSIONS These results support the importance of MPC, especially MPC1, in improving prognostication of IDH-mutant tumors. The generation of a risk score system directly translates this finding to clinical application; however, further research to improve the molecular understanding of the role of MPC in the metabologenomic regulation of gliomas is warranted.
引用
- Karsy M, Guan J, Huang LE, et al. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. J Neurosurg. 2019. PMID: 29547090. doi:10.3171/2017.9.JNS172036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。